GGrantIndex
Sort

40,608 grants matching prostate cancer

RISK FACTORS FOR ADVANCED PROSTATE CANCER

$588,277
University Of Southern California · R01 · FY2003 · CA

CHEMICAL AGONISTS OF THE PML/DAXX PATHWAY FOR PROSTATE CANCER THERAPY

$588,267
Sanford Burnham Prebys Medical Discovery Institute · · FY2008 · Department of the Army

PET-determined prostate brachytherapy dosing using intraoperative image-guidance

$588,227
Daniel Song · Johns Hopkins University · R01 · FY2020 · CA

A Sustainable Approach to Increasing Cancer Screening in Community Health Centers

$588,226
Karen M Emmons · Dana-Farber Cancer Inst · R01 · FY2009 · CA

Research Infrastructure Core

$588,199
Song Gao · Texas Southern University · U54 · FY2022 · MD

Elucidation of the mechanisms by which cells recognize and respond to different levels of androgens

$588,140
Donald P McDonnell · Duke University · R01 · FY2025 · CA

Phase III Trial of Selenium for Prostate Cancer Prevention

$588,097
Frederick R Ahmann · University Of Arizona · R01 · FY2008 · CA

Novel Approaches Targeting B7-H3 in Castration-resistant Prostate Cancer

$588,065
Di Zhao · University Of Tx Md Anderson Can Ctr · R01 · FY2023 · CA

Novel Approaches Targeting B7-H3 in Castration-resistant Prostate Cancer

$588,065
Di Zhao · University Of Tx Md Anderson Can Ctr · R01 · FY2025 · CA

Project 1 - Epigenetic Control of Normal and Malignant Neuroendocrine Differentiation

$588,058
Ramesh A Shivdasani · Dana-Farber Cancer Inst · P01 · FY2025 · CA

Testing Effective Methods to Recruit Sexual and Gender Minority Cancer Patients for Cancer Studies

$588,034
B. R. Simon Rosser · University Of Minnesota · R01 · FY2023 · CA

Clinical Translation of dual-modality transrectal ultrasound and photoacoustic imaging for detection of aggressive human prostate cancer

$588,018
Sri Rajasekhar Kothapalli · Pennsylvania State University, The · R01 · FY2024 · CA

Technetium and Rhenium in Nuclear Medicine

$587,899
Alun Gareth Jones · Harvard Medical School · R01 · FY2010 · CA

Reuse of ZD4054 for patients with symptomatic PAD

$587,704
Brian H Annex · University Of Virginia · UH3 · FY2013 · TR

Reuse of ZD4054 for patients with symptomatic PAD

$587,704
Brian H Annex · University Of Virginia · UH3 · FY2014 · TR

Hybrid Nanoparticles in Imaging and Therapy of Prostate*

$587,694
Kattesh V Katti · University Of Missouri-Columbia · R01 · FY2007 · CA

GENE-ENVIRONMENT INTERACTIONS: THE ODYSSEY COHORT

$587,656
Johns Hopkins University · U01 · FY2003 · AG

Internet-Based Lifestyle Intervention to Eradicate Obese Frailty in Prostate Cancer Survivors (iLIVE)

$587,585
Kerri M Winters-Stone · Oregon Health & Science University · R01 · FY2023 · CA

GENE-ENVIRONMENT INTERACTIONS: THE ODYSSEY COHORT

$587,315
Johns Hopkins University · U01 · FY2002 · AG

Improving Prostate Cancer Outcome Prediction Through Noninvasive exRNA Assessment

$587,298
Matthew R Cooperberg · University Of California, San Francisco · R01 · FY2019 · CA

Glycoprotein biomarkers for the early detection of aggressive prostate cancer

$587,230
Hui Zhang · Johns Hopkins University · U01 · FY2012 · CA

EARLY DETECTION OF PROSTATE CANCER WITH NEW NANOPARTICALES-BASED ULTRASOUND CONTRAST AGENTS TARGETED TO PSMA

$587,222
Case Western Reserve University · · FY2016 · Department of Defense

KINASE INHIBITORS PRESENT EXCITING THERAPIES FOR CANCER INCLUDING PROSTATE CANCER.

$587,220
University Of Washington · · FY2017 · Department of the Army

Genetics and Molecular Mechanisms of Prostate Cancer

$587,204
William Douglas Figg · Division Of Basic Sciences - Nci · ZIA · FY2025 · CA

GENETICS OF PROSTATE CANCER SUSCEPTIBILITY

$587,183
Fred Hutchinson Cancer Research Center · R01 · FY2000 · CA